Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Neumora Therapeutics, Inc. (NMRA)

0.4738 +0.0468 (+10.96%)
At close: October 16 at 4:00:01 PM EDT
0.4722 -0.0016 (-0.34%)
After hours: October 16 at 7:59:32 PM EDT
Trade NMRA on Coinbase
Chart Range Bar
Loading chart for NMRA
  • Previous Close 0.4270
  • Open 0.4366
  • Bid 0.4741 x 100
  • Ask 0.4600 x 200
  • Day's Range 0.4200 - 0.5062
  • 52 Week Range 0.3150 - 3.6500
  • Volume 3,524,374
  • Avg. Volume 1,370,598
  • Market Cap (intraday) 89.025M
  • Beta (5Y Monthly) 2.97
  • PE Ratio (TTM) --
  • EPS (TTM) -1.2300
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 6.14
  • Zacks Rating Bullish

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

www.neumoratx.com

63

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NMRA
73.53%
S&P 500 (^GSPC)
11.89%

1-Year Return

NMRA
73.38%
S&P 500 (^GSPC)
15.54%

3-Year Return

NMRA
95.68%
S&P 500 (^GSPC)
75.13%

5-Year Return

NMRA
97.21%
S&P 500 (^GSPC)
71.30%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -53.46M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

3.00
6.14 Average
0.4738 Current
14.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/13/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 7 -> 5

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    137.41M

  • Enterprise Value

    73.83M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.09

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -73.85%

  • Return on Equity (ttm)

    -187.11%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -212.74M

  • Diluted EPS (ttm)

    -1.2300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    116.83M

  • Total Debt/Equity (mrq)

    119.62%

  • Levered Free Cash Flow (ttm)

    -99.42M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.4738 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: